Get all the news you need in your inbox each morning. The medical service/device: The iLet Bionic Pancreas, an insulin pump. The service provider: CCS, a medical supplies distributor. The bill ...

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 million in the fourth quarter.

approval of its iLet insulin delivery system for type 1 diabetes in mid-2023. An artificial pancreas, also known as a ...

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

Its iLet product is the first FDA cleared pump which uses adaptive and closed-loop algorithms driven by body weight, with no additional insulin design parameters being used. Such adaptive ...

Transplants, insulin pumps, software that recognizes and adjusts ... Damiano expects his bionic pancreas, called the iLet, to become commercially available within a year or so.

Its patch pump will feature one component for the electronics and monitor, and another disposable element for the insulin reservoir, adhesive, insertion device and cannula. It will utilize the same ...

The iLet was specifically designed to provide improvements in glycemic control relative to currently available treatment options, such as insulin pumps, including partially automated insulin ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

The so-called 'hybrid closed-loop' system comprises a blood glucose sensor, the MiniMed 670G insulin pump and an infusion ... Beta Bionics' iLet has shown promise in clinical trials so far.